Clinical Trial Update: Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating PF-04965842 and dupilumab for adult moderate-to-severe atopic dermatitis on topical therapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)
• PF-04965842

Snippet

Sponsor: Pfizer | Conditions: Dermatitis, Dermatitis, Atopic | Phase 3 | Status: COMPLETED | Results posted: 2021-01-19